One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide value to stakeholders, both for investors and patients. At OSE Immunotherapeutics we implemented a business model that allows us to be one of the rare French biotech companies without commercial products able to generate revenue and advance multiple clinical stage assets without needing dilutive funding since our 2015 IPO.